Brawn Biotech Ltd Stock Price Today (NSE: BRAWN)
Fundamental Score
Brawn Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Brawn Biotech Ltd share price today is ₹20.85, down 0.71% on NSE/BSE as of 30 March 2026. Brawn Biotech Ltd (BRAWN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.78 (Cr). The 52-week high for BRAWN share price is ₹24.37 and the 52-week low is ₹15.70. The company has a Return on Equity (ROE) of -41.33% and a debt-to-equity ratio of 0.00.
Brawn Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Brawn Biotech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Brawn Biotech Share Price: A Financial Stability Analysis
The pharmaceutical industry, known for its high barriers to entry due to stringent regulations and extensive R&D, faces constant pressure to innovate. This analysis examines the financial stability of Brawn Biotech Ltd, focusing on its current performance metrics. The current Brawn Biotech share price stands at ₹18.51. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
One immediate concern is the absence of a Price-to-Earnings (PE) ratio. This typically indicates that the company is not currently profitable, making valuation difficult using traditional metrics. Furthermore, a Return on Capital Employed (ROCE) of -42.52% signals significant challenges in generating profits from its invested capital. This negative ROCE erodes the company's economic moat, as it demonstrates an inability to efficiently deploy capital and achieve competitive returns compared to its cost of capital.
Comparing Brawn Biotech Ltd to sector peers provides further context.
Mankind Pharma Ltd, for instance, generally commands higher valuations reflecting, among other factors, market perception of management quality and operational efficiency. While a direct comparison of management capabilities is beyond the scope of this analysis, the stark contrast in financial performance suggests potentially different approaches to resource allocation and strategic execution. The management quality of Mankind Pharma Ltd is perceived to be much better based on the current stock performance. It is important to note that financial performance does not provide any reflection on the ethical conduct of the board.In conclusion, while the current Brawn Biotech share price might appear attractive, the negative ROCE and lack of a PE ratio warrant careful consideration. The company's ability to improve its capital efficiency and achieve profitability will be crucial for its long-term financial stability. Future analysis should focus on understanding the underlying reasons for the negative ROCE and evaluating the company's plans for turnaround.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Brawn Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BRAWN across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (120.59%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (48.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (53.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-41.33%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-42.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-6.41%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (-22.97% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.35%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Brawn Biotech Ltd Financial Statements
Comprehensive financial data for Brawn Biotech Ltd including income statement, balance sheet and cash flow
About BRAWN (Brawn Biotech Ltd)
Brawn Biotech Ltd is a dynamic pharmaceutical company deeply rooted in the Indian healthcare landscape. Established in 1985 and headquartered in New Delhi, Brawn Biotech has evolve...d to become a significant player in the trading and distribution of a diverse range of pharmaceutical products. The company operates with a commitment to providing accessible and affordable healthcare solutions across various therapeutic areas. Brawn Biotech's portfolio is carefully curated to address the prevalent health needs of the Indian population, ensuring that essential medications reach those who need them most. Through strategic partnerships and a robust distribution network, Brawn Biotech diligently works to strengthen its presence and impact in the ever-evolving pharmaceutical sector. Brawn Biotech distinguishes itself by offering a comprehensive spectrum of pharmaceutical formulations designed to tackle a multitude of health challenges. Their product line encompasses critical medications addressing widespread ailments, including antibacterial agents to combat infections, cardiovascular drugs for heart health, and antidiabetic medications for managing diabetes. Furthermore, Brawn Biotech provides solutions for pain relief with their range of analgesics, digestive health through gastrointestinal formulations, and dermatological well-being with specialized skin care products. The company also caters to mental health with antipsychotic drugs, respiratory conditions with antiasthmatic medications, and offers relief from digestive discomfort with antacids. Brawn Biotech further contributes to public health by providing antimalarial drugs and essential nutritional products. Brawn Biotech operates with a forward-thinking approach, consistently adapting to the changing dynamics of the pharmaceutical industry. The company's commitment to quality and accessibility is reflected in its extensive product range and its dedication to reaching diverse patient populations. Formerly known as Brawn Pharmaceuticals Limited, the strategic name change to Brawn Biotech Limited in 2010 signaled a broader vision and a renewed focus on innovation and growth. With decades of experience in the Indian pharmaceutical market, Brawn Biotech is poised to further expand its reach and contribute to improving the health and well-being of communities across the nation.
Company Details
Key Leadership
Corporate Events
Latest News
BRAWN Share Price: Frequently Asked Questions
What is the current share price of Brawn Biotech Ltd (BRAWN)?
As of 30 Mar 2026, 11:00 am IST, Brawn Biotech Ltd share price is ₹20.85. The BRAWN stock has a market capitalisation of ₹5.78 (Cr) on NSE/BSE.
Is BRAWN share price Overvalued or Undervalued?
BRAWN share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Brawn Biotech Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of BRAWN share price?
The 52-week high of BRAWN share price is ₹24.37 and the 52-week low is ₹15.70. These values are updated daily from NSE/BSE price data.
What factors affect the Brawn Biotech Ltd share price?
Key factors influencing BRAWN share price include quarterly earnings growth (Sales Growth: 48.18%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Brawn Biotech Ltd a good stock for long-term investment?
Brawn Biotech Ltd shows a 5-year Profit Growth of N/A% and an ROE of -41.33%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in BRAWN shares.
How does Brawn Biotech Ltd compare with its industry peers?
Brawn Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare BRAWN share price P/E of 0.00x and ROE of -41.33% against the industry averages to determine competitive standing.
What is the P/E ratio of BRAWN and what does it mean?
BRAWN share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is BRAWN performing according to Bull Run's analysis?
BRAWN has a Bull Run fundamental score of 28/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BRAWN belong to?
BRAWN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Brawn Biotech Ltd share price.
What is Return on Equity (ROE) and why is it important for BRAWN?
BRAWN has an ROE of -41.33%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Brawn Biotech Ltd generates profits from shareholders capital.
How is BRAWN debt-to-equity ratio and what does it indicate?
BRAWN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is BRAWN dividend yield and is it a good dividend stock?
BRAWN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Brawn Biotech Ltd shares.
How has BRAWN share price grown over the past 5 years?
BRAWN has achieved 5-year growth rates of: Sales Growth -22.97%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BRAWN and why does it matter?
Promoters hold 53.66% of BRAWN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Brawn Biotech Ltd.
What is BRAWN market capitalisation category?
BRAWN has a market capitalisation of ₹6 crores, placing it in the Small-cap category.
How volatile is BRAWN stock?
BRAWN has a beta of N/A. A beta > 1 suggests the Brawn Biotech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BRAWN operating profit margin trend?
BRAWN has a 5-year average Operating Profit Margin (OPM) of -6.41%, indicating the company's operational efficiency.
How is BRAWN quarterly performance?
Recent quarterly performance shows Brawn Biotech Ltd YoY Sales Growth of 48.18% and YoY Profit Growth of 120.59%.
What is the institutional holding pattern in BRAWN?
BRAWN has FII holding of 0.00% and DII holding of 0.35%. Significant institutional holding often suggests professional confidence in the Brawn Biotech Ltd stock.